{
    "clinical_study": {
        "@rank": "124183", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1: BMS-852927 (0.25 mg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm 2: BMS-852927 (1.0 mg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm 3: BMS-852927 (2.5 mg)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm 4: Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety of BMS-852927 after 28 days of dosing in\n      patients with high cholesterol."
        }, 
        "brief_title": "A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women, aged \u226518 to \u226475\n\n          -  Body mass index (BMI) \u2264 40 kg/m2\n\n          -  Primary hypercholesterolemia on a stable daily dose of a statin for \u2265 6 weeks\n\n          -  Serum triglyceride levels at screening < 400mg/dL (< 4.52 mmol/L)\n\n        Exclusion Criteria:\n\n          -  Any significant acute medical illness, significant cardiovascular history\n\n          -  Current or history of hepatic or hepatobiliary disease\n\n          -  Evidence of organ dysfunction or any clinically significant deviation from normal in\n             physical examination, vital signs, ECG or clinical laboratory determinations beyond\n             what is consistent with the target population"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "97", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651273", 
            "org_study_id": "CV201-008", 
            "secondary_id": "2012\u2010001946\u201017"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1: BMS-852927 (0.25 mg)", 
                "description": "Capsules, Oral, 0.25 mg, Once daily, 28 days", 
                "intervention_name": "BMS-852927", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2: BMS-852927 (1.0 mg)", 
                "description": "Capsules, Oral, 1.0 mg, Once daily, 28 days", 
                "intervention_name": "BMS-852927", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 3: BMS-852927 (2.5 mg)", 
                "description": "Capsules, Oral, 2.5 mg, Once daily, 28 days", 
                "intervention_name": "BMS-852927", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 4: Placebo", 
                "description": "Capsules, Oral, 0 mg, Once daily, 28 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 2, 2013", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brampton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L6T 0G1"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4G 3E8"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pointe-Claire", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H9R 4S3"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Victoriaville", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G6P 6P6"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G3K 2P8"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G1N 4V3"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neuss", 
                        "country": "Germany", 
                        "zip": "41460"
                    }, 
                    "name": "Local Institution"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "Germany"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Site and Subject Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS 852927 in Patients With Primary Hypercholesterolemia on a Stable Dose of Statin Therapy", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Canada: Health Canada", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number and percent of subjects that experience the Serious adverse events, Deaths, Adverse events leading to discontinuation of study therapy", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 56 days of study participation"
            }, 
            {
                "measure": "Number and percent of subjects that experience the Serious adverse events, Deaths, Adverse events leading to discontinuation of study therapy", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days post discontinuation of dosing or last participation in the study for serious adverse events collection"
            }, 
            {
                "description": "Electrocardiogram (ECG) parameters defined as:\nInvestigator identified clinically significant abnormalities\nQTcF> 480 msec or QTcF changes from baseline> 60 msec\nQRS (msec): QRS> 120 msec\nPR (msec): PR > 210 msec", 
                "measure": "Number and percent of subjects with potentially clinically significant changes in ECG parameter", 
                "safety_issue": "Yes", 
                "time_frame": "Upto 56 days"
            }, 
            {
                "description": "LDL-c (measured) defined as:\nLDL-c (mg/dL): LDL-c percent changes from baseline >= 15%", 
                "measure": "Number and percent of subjects with potentially clinically significant changes in low density lipoprotein (LDL)-c (measured)", 
                "safety_issue": "Yes", 
                "time_frame": "Upto 56 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651273"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Trough observed concentration (Cmin) of BMS-852927 will be derived from plasma concentration versus time data", 
                "safety_issue": "No", 
                "time_frame": "Days 7, 14, 21 and 28"
            }, 
            {
                "measure": "Area under the concentration-time curve from zero (pre-dose) to 8 h [AUC(0-8h)] of BMS-852927 will be derived from plasma concentration versus time data", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 28"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}